Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on IMUX stock, giving a Buy rating on May 13.

Myles Minter has given his Buy rating due to a combination of factors surrounding Immunic’s current and future prospects. One of the key reasons is the promising clinical data from the Phase IIb CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (MS), which suggests potential disease-modifying effects in a challenging patient population. This positive outcome positions Immunic well for advancing into pivotal Phase III trials, which could significantly enhance the company’s value if successful.
Minter also considers the financial aspects, noting that while Immunic has a limited cash runway, there is potential for additional funding through a tranche from a previous PIPE agreement, contingent on stock performance. The anticipated release of top-line data from the ENSURE-1/2 trials in relapsing MS in 2026 further supports the long-term investment thesis, as these results could provide additional validation of the company’s therapeutic approach. Overall, these elements contribute to a favorable outlook for Immunic, justifying the Buy rating.

In another report released on May 13, Leerink Partners also reiterated a Buy rating on the stock with a $6.00 price target.